For expectant mothers, the diagnosis of preeclampsia often arrives too late, a dangerous complication marked by high blood pressure that can escalate into seizures or organ failure. The standard screening today is a blunt instrument, relying on maternal history and blood pressure readings that often miss the risk until symptoms are severe. A Vienna-based startup, Aitiologic, is betting its entire seed funding that a more precise signal can be found in a vial of blood, years before a patient ever shows symptoms.
Founded in 2023, Aitiologic is building what it calls a tissue-resolved liquid biopsy platform. Its core technology, named Aitios, analyzes circulating cell-free DNA (cfDNA) using a combination of genomic, epigenomic, and fragmentomic signals. The goal is not just to detect genetic anomalies, but to pinpoint their tissue of origin and the biological changes associated with early disease [aitiologic.com, retrieved 2024]. For its first clinical target, the company is bypassing the crowded field of oncology to tackle a clear, unmet need in maternal-fetal health: first-trimester risk assessment for preeclampsia.
A Foundational Bet on Multi-Modal Signals
Liquid biopsy is a promising but noisy field. Detecting cancer signals from cfDNA is famously challenging, akin to finding a specific sentence in a library of shredded books. Aitiologic's technical wedge is its claim to add "tissue-specific resolution" by analyzing multiple data layers from a single blood draw [aitiologic.com, retrieved 2024]. The Aitios platform is designed to interpret not just what DNA fragments are present, but how they are modified and broken up, which can reveal their cellular source and the state of that tissue.
This multi-modal approach is the foundation of the company's broader ambition. While the lead program is in prenatal care, earlier company materials described a vision extending into non-invasive prenatal testing (NIPT) and oncology [viennabiocenter.org, retrieved 2024]. The preeclampsia test serves as a clinical and regulatory proving ground. If Aitiologic can demonstrate accurate, early risk stratification for this complex condition, it validates the platform's core technology for other applications where tissue-of-origin analysis is critical.
The Team and Its Licensed Edge
The company's origins are deeply technical, rooted in intellectual property developed within a diagnostics giant. Dr. Andreas E. Posch, founder and CEO, co-invented the patented tissue-specific liquid biopsy technology while at Siemens Healthineers. That IP has been exclusively licensed to Aitiologic, providing a head start that is rare for a seed-stage biotech [startup.eu, September 2026]. Co-founder and CTO Stephan Beisken rounds out the founding team.
Perhaps the most significant signal of credibility came with Aitiologic's September 2026 financing. The €6.4 million seed round was co-led by Heal Capital and Ananda Impact Ventures, and it attracted Dr. Gordon Sanghera CBE FRS, co-founder and former CEO of Oxford Nanopore Technologies, as an investor and advisory board member [Brandl Talos, September 2026]. Sanghera's involvement, given his background in pioneering novel sequencing platforms, is a notable endorsement of the underlying technical approach.
The company's funding history shows steady, staged support from European healthtech and impact investors.
Oct 2024 Seed | 2.7 | M USD
Sep 2026 Seed | 6.9 | M USD
The Road to Clinical Validation
The path from a promising platform to a clinically adopted diagnostic is long, expensive, and fraught with regulatory scrutiny. Aitiologic has not yet disclosed named commercial customers, clinical trial data, or partnerships with diagnostic labs or pharmaceutical companies. This is typical for a company at this stage, but it defines the critical milestones for the newly raised capital. The proceeds are earmarked to advance the Aitios platform and the preeclampsia lead program [GlobeNewswire, September 2026].
The company's public focus on first-trimester testing places it in a specific regulatory category. In Europe, such tests would need to navigate the In Vitro Diagnostic Regulation (IVDR), a rigorous framework for clinical evidence. In the U.S., the path would involve the FDA, likely as a Class II or III device depending on the claimed intended use and risk. Aitiologic has not publicly detailed its regulatory strategy, but the choice of preeclampsia,a serious condition with limited early detection options,could help frame the test's clinical necessity.
An Honest Counterfactual
For all its technical promise, Aitiologic faces a landscape of well-funded competitors and scientific uncertainty. The liquid biopsy space is crowded with companies focused primarily on oncology, many with later-stage clinical data and commercial launches. By choosing preeclampsia as its wedge, Aitiologic is betting on a less contested but also less proven market. The biology of preeclampsia is complex and not fully understood, which makes identifying a reliable cfDNA signature exceptionally difficult.
The company's most plausible answer to these challenges is its licensed IP and multi-modal approach. The Siemens-originated technology provides a differentiated starting point, and the focus on tissue resolution, rather than just mutation detection, could unlock signals others miss. Furthermore, success in the prenatal setting could create a springboard into adjacent women's health conditions, like gestational diabetes, before ever touching the competitive oncology arena [aitiologic.com, retrieved 2024].
What to Watch in the Next Twelve Months
The coming year will be about transitioning from platform development to clinical proof. Key milestones will include the publication of analytical validation data, the initiation of a clinical study for the preeclampsia assay, and the announcement of its first laboratory or healthcare system partnership. The hiring of an assay development scientist, as indicated by a job posting on its site, points to the internal work of translating the platform into a reproducible diagnostic test [aitiologic.com, retrieved 2024].
For the patients Aitiologic aims to serve, the stakes are profoundly human. Preeclampsia affects roughly 2-8% of pregnancies globally and remains a leading cause of maternal and infant morbidity and mortality. The current standard of care involves monitoring blood pressure and protein in urine, with definitive treatment often being the early delivery of the baby, which carries its own risks for the newborn. A reliable, early blood test that could stratify risk in the first trimester would represent a paradigm shift, allowing for closer monitoring and preventive interventions for those who need it most.
Sources
- [aitiologic.com, retrieved 2024] aitiologic | Liquid Biopsy for Precision Medicine | https://www.aitiologic.com/
- [viennabiocenter.org, retrieved 2024] Aitiologic Emerges from Stealth Mode | https://www.viennabiocenter.org/about/news/aitiologic-emerges-from-stealth-mode/
- [startup.eu, September 2026] Startup.eu profile | https://www.startup.eu/startup/aitiologic
- [Brandl Talos, September 2026] BRANDL TALOS advises Aitiologic on EUR 6.4 million seed financing round | https://brandltalos.com/en/insight/brandl-talos-advises-aitiologic-on-eur-6-4-million-seed-financing-round/
- [GlobeNewswire, September 2026] Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing | https://www.globenewswire.com/news-release/2026/09/15/3361783/0/en/aitiologic-raises-6-4-million-in-oversubscribed-seed-financing-to-advance-tissue-resolved-liquid-biopsy-platform-and-preeclampsia-lead-program.html
- [Brutkasten, October 2024] Aitiologic: Wiener Diagnostik-Startup verlässt mit 2,5 Mio. Euro-Finanzierung 'Stealth Mode' | https://brutkasten.com/artikel/aitiologic-finanzierung